Skip to main content
. 2011 Mar 15;2011:362173. doi: 10.1155/2011/362173

Table 1.

Summary of copy number alternations (CNAs) in Ewing's Sarcoma (tumor, cell line, and xenograft) in published literature.

Deletion Gain Ewing's sample type Frequency (%) Technology Study Clinical significance
1p ESFT 17/184 (9%) Karyotyping and CGH Hattinger et al. [47]; Ozaki et al. [48]
1p36 ESFT 5/88 (6%) Karyotyping (G-Band) Roberts et al. [49]
1p36.32-p36.11 ESFT 2/9 (22%) SNP Microarray (Affy 100 K) Neale et al. [50]
1q ESFT 77/396 (19%) Karyotyping and CGH Armengol et al. [51]; Brisset et al. [52]; Hattinger et al. [47]; Ozaki et al. [48]; Roberts et al. [49]; Savola et al. [53]; Tarkkanen et al. [54] (i) Adverse event free survival (ii) Adverse overall survival (iii) Age at diagnosis >15 years (iv) Metastatic (trend)
Cell line 5/8 (63%) CGH Shing et al. [55]
1q21-q22 ESFT 5/28 (18%) CGH Tarkkanen et al. [54] (i) Adverse overall survival (trend) (ii) Adverse 5-year distant disease-free survival (trend)
2 ESFT 38/262 (15%) Karyotyping and CGH Brisset et al. [52]; Hattinger et al. [47]; Roberts et al. [49], Savola et al. [53] (i) Localized disease
2q ESFT 12/62 (19%) CGH Ozaki et al. [48] (i) Adverse overall survival
3p Cell line 3/8 (38%) CGH Shing et al. [55]
4p ESFT 10/105 (10%) CGH Brisset et al. [52]; Ozaki et al. [48] (i) Relapse
5 ESFT 28/231 (12%) Karyotyping and CGH Brisset et al. [52]; Hattinger et al. [47]; Roberts et al. [49]
5p ESFT 5/25 (20%) CGH Ferreira et al. [56]
6p21.1~pter ESFT 3/28 (11%) CGH Tarkkanen et al. [54] (i) Adverse overall survival (ii) Adverse 5-year distant disease-free survival
7 ESFT 26/216 (12%) Karyotyping and CGH Hattinger et al. [47]; Roberts et al. [49]; Tarkkanen et al. [54]
7p21.1-p11.2 ESFT 2/9 (22%) SNP Microarray (Affy 100 K) Neale et al. [50]
7q (partial) ESFT 6/25 (25%) CGH Ferreira et al. [56]
7q ESFT 5/28 (18%) CGH Tarkkanen et al. [54]
8 ESFT 197/413 (48%) Karyotyping, CGH and FISH Armengol et al. [51]; Brisset et al. [52]; Ferreira et al. [56]; Hattinger et al. [47]; Maurici et al. [57]; Ozaki et al. [48]; Savola et al. [53]; Tarkkanen et al. [54]; Zielenska et al. [58] (i) Local recurrences (trend) (ii) Relapse (trend) (iii) Adverse overall survival (trend) (iv) Adverse 5-year distant disease-free survival (trend)
Cell line 8/8 (100%) CGH Shing et al. [55]
8p ESFT 30/62 (48%) CGH Ozaki et al. [48] (i) Relapse
8q ESFT 32/62 (52%) CGH Ozaki et al. [48]
8q11.21-q22.3 ESFT 6/9 (67%) SNP Microarray (Affy 100 K) Neale et al. [50]
8q24.11-q24.21 ESFT 7/9 (78%) SNP Microarray (Affy 100 K) Neale et al. [50]
9p ESFT 7/31 (23%) CGH Savola et al. [53]
9p21 ESFT 50/291 (17%) Karyotyping, CGH, FISH, Southern Blot, SNP Microarray (Affy 100 K), and MLPA Brownhill et al. [59]; Huang et al. [60]; Kovar et al. [61]; Neale et al. [50]; Roberts et al. [49]; Savola et al. [62]; Wei et al. [63] (i) Adverse event free survival (trend) (ii) Adverse overall survival(iii) Axial(iv) progressive disease (trend) (v) Poor chemoresponse
9p21 Cell line 24/43 (56%) CGH (Agilent 44 K and 244 K), Taqman qRT-PCR, FISH, Southern Blot and MLPA Brownhill et al. [59]; Kovar et al. [61]; Savola et al. [62]
9p21.3 Xenotransplant 4/12 (33%) dPCR, FISH López-Guerrero et al. [64]
10 ESFT 12/87 (14%) CGH Ferreira et al. [56]; Ozaki et al. [48]
11p ESFT 2/62 (3%) Ozaki et al. [48] (i) Relapse
11q ESFT 2/62 (3%) Ozaki et al. [48] (i) Relapse
12 ESFT 104/434 (24%) Karyotyping, CGH and FISH Armengol et al. [51]; Brisset et al [52]; Ferreira et al. [56]; Hattinger et al. [47]; Maurici et al. [57]; Roberts et al. [49]; Savola et al. [53]; Tarkkanen et al. [54]; Zielenska et al. [58] (i) Adverse event free survival (ii) Adverse overall survival(iii) Relapse (trend)
12p ESFT 12/62 (19%) CGH Ozaki et al. [48] (i) Adverse overall survival
12q ESFT Cell line 11/62 (18%) 6/8 (75%) CGH CGH Ozaki et al. [48]Shing et al. [55] (i) Adverse overall survival
12q14.1-q15 ESFT 2/9 (22%) SNP Microarray (Affy 100 K) Neale et al. [50]
14 ESFT 11/143 (8%) Karyotyping and CGH Brisset et al. [52]; Hattinger et al. [47]
14q11.2 ESFT 2/9 (22%) SNP Microarray (Affy 100 K) Neale et al. [50]
15 ESFT 4/43 (9%) CGH Brisset et al. [52]
16p ESFT 2/28 (7%) CGH Tarkkanen et al. [54]
16q ESFT 69/396 (17%) Karyotyping and CGH Brisset et al. [52]; Ferreira et al. [56]; Hattinger et al. [47]; Ozaki et al. [48]; Roberts et al. [49]; Savola et al. [53]; Tarkkanen et al. [54] (i) Adverse overall survival(ii) Age at diagnosis >15 years(iii) Disseminated disease at diagnosis
16q Cell line 5/8 (63%) CGH Shing et al. [55]
16q22.3 ESFT 5/9 (56%) SNP Microarray (Affy 100 K) Neale et al. [50]
17 ESFT and Xenotransplant 2/19 (11%) dPCR, FISH López-Guerrero et al. [64]
17p ESFT Cell line 9/62 (15%) 4/8 (50%) CGH CGH Ozaki et al. [48] Shing et al. [55] (i) Adverse overall survival
17p13 ESFT 8/88 (9%) Karyotyping (G-Band) Roberts et al. [49]
17q21.31-q25.3 ESFT 6/9 (67%) SNP Microarray (Affy 100 K) Neale et al. [50]
18 ESFT 6/68 (9%) CGH Brisset et al. [52]; Ferreira et al. [56]
19 ESFT 4/25 (16%) CGH Ferreira et al. [56]
19p ESFT 7/62 (11%) CGH Ozaki et al. [48]
19q ESFT 11/62 (18%) CGH Ozaki et al. [48]
20 ESFT 35/248 (14%) Karyotyping and CGH Brisset et al. [52]; Ferreira et al. [56]; Hattinger et al. [47]; Roberts et al. [49] (i) Adverse event free survival (ii) Adverse overall survival
20p ESFT 11/62 (18%) CGH Ozaki et al. [48] (i) Adverse overall survival
20q ESFT 11/62 (18%) CGH Ozaki et al. [48] (i) Adverse overall survival
20q11.23-q13.33 ESFT 2/9 (22%) SNP Microarray (Affy 100 K) Neale et al. [50]
21q22.3 ESFT 2/9 (22%) SNP Microarray (Affy 100 K) Neale et al. [50]
22q11.21 ESFT 2/9 (22%) SNP Microarray (Affy 100 K) Neale et al. [50]
Y Cell lines 3/5 (60%) CGH Shing et al. [55]

*Modified from Toomey et al. Oncogene 2010. ESFT: Ewing's Sarcoma Family of Tumors, CGH: comparative genomic hybridization.